Wearing-off and Parkinson's: Research papers
- The Q10 questionnaire for detection of wearing-off phenomena in Parkinson's disease
Q10 items were selected from the QUICK validation study data set through statistical analysis and it was then tested on a sample of 162 PD patients, 64.8% with wearing-off. Sensitivity, specificity, and accuracy were 96%, 63%, and 85% respectively with one positive response and 90%, 70%, and 83% respectively with two positive responses.
12 January 2012
- Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease
Patients with Parkinson's disease experience motor and perceptual timing difficulties, which are ameliorated by dopaminergic medication. We investigated the neural correlates of motor timing in Parkinson's disease, including the effects of dopaminergic medication on patterns of brain activation.
16 March 2010
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
This study was performed to assess the long-term antidyskinetic effect of amantadine in PD patients. The findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's.
02 March 2010
- Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy.
Conclusion: Nonmotor symptoms of PD appear sensitive to dopaminergic treatment. These symptoms resemble those seen with depressive, anxiety, and somatoform disorders suggesting potential shared mechanisms as well as possible treatment implications.
01 February 2010
- Orodispersible sublingual piribedil to abort OFF episodes
A single dose placebo-controlled, randomized, double-blind, cross-over study. S90049, a novel sublingual formulation of the non-ergoline D(2)-D(3) agonist piribedil, has a pharmacokinetic profile promising to provide rapid relief on motor signs in Parkinson's disease (PD).
12 January 2010
- Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease.
In this paper the authors describe the retrospective development of a simpler, 19-symptom WOQ more suitable for routine clinical use.
01 February 2007
